Huntington’s Disease Treatment Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Huntington’s Disease Treatment Market Grown from 2024 to 2025?#_x000D_
The market size for Huntington’s disease treatment has expanded swiftly over the recent years. The projections indicate that the market will escalate from $0.73 billion in 2024 to $0.83 billion in 2025, marking a compound annual growth rate (CAGR) of 13.3%. Factors contributing to this historical period growth are heightened awareness of genetic disorders, enhanced accessibility to genetic testing, increased investment in research for neurodegenerative diseases, a surge in the number of clinical trials for tentative therapies, and the expanding roster of disease-modifying drugs._x000D_
_x000D_
#What Growth Rate Is Anticipated for the Huntington’s Disease Treatment Market in the Coming Years?#_x000D_
The market size for treating Huntington’s disease is projected to undergo notable expansion in the coming years. The expectation is that it will increase to $1.35 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.0%. This period of rapid growth can be associated with factors such as an increased emphasis on personalized medicine, the further integration of digital health-tracking tools, increased regulatory assistance for rare disease drugs, a surge in demand for therapies providing symptomatic reprieve, and a rise in need for treatments that directly modify the disease’s progression. Major forecasts for this period involve the use of technology in creating gene silencing tools, the development of cell-based therapies and peripheral biomarkers, the inclusion of telehealth in Huntington’s disease management, the collection of patient-reported results, and innovative advancements in drugs that modify the disease._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp_x000D_
_x000D_
#Who Are the Leading Companies in the Huntington’s Disease Treatment Market?#_x000D_
Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V._x000D_
_x000D_
#What Are the Key Drivers of the Huntington’s Disease Treatment Market?#_x000D_
The surge in gene therapies is anticipated to fuel the expansion of the Huntington’s disease treatment market in the future. These therapies involve modifying or substituting faulty genes in order to prevent or cure diseases at a genetic level. As precision medicine makes strides, gene therapies are becoming more prevalent, directly addressing genetic causes and yielding improved results compared to conventional treatments. Gene therapies confront Huntington’s disease by muting the faulty HTT gene that produces damaging proteins, thereby shielding nerve cells. This approach aids in slowing the progression of the disease, safeguarding brain functionality, and potentially enabling long-term control. For example, based on data from the American Society of Gene & Cell Therapy (ASGCT), a professional organization based in the U.S., and Citeline, a U.S. supplier of drugs and devices, by the end of the first quarter of 2023, 247 gene therapies were in Phase II. However, by the end of the second quarter, that number had grown by 5% to 260. Consequently, the rise in gene therapies is propelling the expansion of the Huntington’s disease treatment market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp_x000D_
_x000D_
#What Are the Key Market Segments in the Huntington’s Disease Treatment Industry?#_x000D_
The huntington’s disease treatment market covered in this report is segmented –_x000D_
_x000D_
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies_x000D_
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical_x000D_
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders_x000D_
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers_x000D_
_x000D_
Subsegments_x000D_
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers_x000D_
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies_x000D_
_x000D_
#What Are the Latest Trends in the Huntington’s Disease Treatment Market?#_x000D_
Prominent businesses in the Huntington’s disease treatment market are prioritizing the creation of innovative therapies like Selective Vesicular Monoamine Transporter 2 (VMAT2) inhibitor capsules. These have the potential to enhance the quality of life for patients and decelerate the progression of the disease. VMAT2 inhibitor capsules are a class of drugs that obstruct the VMAT2, a protein that plays a critical role in packaging brain-releasing neurotransmitters. These pharmaceuticals help minimize the release of neurotransmitters, thereby aiding in handling involuntary movements and associated symptoms. For example, in August 2023, the U.S. Food and Drug Administration (FDA) gave the green light to Neurocrine Biosciences, Inc., a bio-technology firm based in the US, for their Ingrezza (valbenazine) capsules. These were intended for treating adults suffering from chorea connected to Huntington’s Disease (HD). The once-daily VMAT2 inhibitor, taken orally, acts by lowering excessive dopamine signalling within the brain, aiding in the management of involuntary movements. This medication, available in several capsule strengths, can be consumed with or without eating, making it a flexible dosing option for patients._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Are the Key Regional Markets in the Huntington’s Disease Treatment Industry?#_x000D_
North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the huntington’s disease treatment market, and how is it changing globally?_x000D_
2. Who are the major companies in the huntington’s disease treatment market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the huntington’s disease treatment market right now?_x000D_
4. Which products or customer segments are growing the most in the huntington’s disease treatment market?_x000D_
5. What factors are helping or slowing down the growth of the huntington’s disease treatment market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
